Eli Lilly is stepping up its fight against copycat weight-loss drugs
In its continuing war against copycat drugs, Eli Lilly (LLY) said on Wednesday that it filed suits against four telehealth companies that offer cheaper versions of its blockbuster GLP-1 weight loss drugs Mounjaro and Zepbound.Read more... [...]
Rating
Innovation
Pricing
Technology
Usability
We have discovered similar tools to what you are looking for. Check out our suggestions for similar AI tools.
How Ozempic maker Novo Nordisk fell behind Eli Lilly in the weight loss drug race
Novo Nordisk (NVO) makes Ozempic, the best-known GLP-1 drug out today. And until quite recently, the Danish pharma giant consistently led the pack in new prescriptions, becoming virtually synonymous w [...]
Verdiva launches with $410M for weight loss drugs to challenge Ozempic, Wegovy
London-headquartered biotech startup Verdiva has emerged from stealth with a whopping $410mn for a new range of drugs aimed at tackling the obesity epidemic. It’s one of Europe’s largest-ever biot [...]
An Ozempic successor falls short, Eli Lilly's GLP-1 pill, and senators grill RFK: Pharma news roundup
An Eli Lilly exec said the company’s experimental weight-loss pill could make GLP-1 treatments more accessible worldwide, as it would be easier to manufacture and distribute globally. Three U.S. sen [...]
Eli Lilly's online health platform just expanded beyond weight loss to tackle Alzheimer’s
Just about a year after launching a direct-to-consumer online platform to sell treatments for diabetes and obesity, Eli Lilly (LLY) is now expanding the program to offer resources for Alzheimer’s d [...]
Eli Lilly signs $2.75 billion deal with AI drug developer Insilico Medicine
US pharmaceutical giant Eli Lilly is betting big on AI-driven drug development, signing a $2.75 billion deal with Hong Kong-listed Insilico Medicine.<br /> The article Eli Lilly signs $2.75 bill [...]